Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2025 15:18 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
March 05, 2025 12:15 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders

Siren Biotechnology expands Clinical and Scientific Advisory Board with key industry leaders
November 18, 2024 11:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA

Siren Biotechnology reveals SRN-101 as lead asset for high-grade gliomas with both Orphan Drug and Rare Pediatric Disease Designations from the FDA
May 08, 2024 11:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer

Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
November 01, 2023 12:46 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)

Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)
May 17, 2023 06:02 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Unveils Preclinical Data for Universal AAV Immuno-Gene Therapy™ for Cancer, a Novel Modality that Combines AAV Gene Therapy and Cytokine Immunotherapy

Data demonstrated that AAV vectors expressing engineered immunomodulatory interferon (IFN) cytokine payloads led to: Rapid and selective reduction in tumor size in high-grade glioma (HGG)...
May 17, 2023 06:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy™ for Cancer

Novel approach combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single transformative modalityBelieved to be the first ever AAV...